Third Party Viral Specific T-cells (VSTs)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age2+
SponsorChildren's Hospital Medical Center, Cincinnati
About this trial
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
Eligibility criteria
Qualifiers
Immunocompromised patient with evidence of viral infection or reactivation
Age >1 day
Recipients who have had a stem cell transplant must be at least 21 days after stem cell infusion
Clinical status must allow tapering of steroids to < 0.5mg/kg prednisone or other steroid equivalent
Disqualifiers
Active acute GVHD grades II-IV
Uncontrolled bacterial or fungal infection
Uncontrolled relapse of malignancy requiring treatment with chemotherapy
Infusion of ATG or alemtuzumab within 2 weeks of VST infusion
Trial design
Treatments tested in this trial
- Viral Specific VST Infusion
Treatment groups
750 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov